Randomization and Kit Lists: What They Are and Why They Matter
A randomization list is a predefined schedule that assigns each study participant to a treatment group using statistically valid, unbiased methods to support internal validity, regulatory compliance, and credible trial data.
What Is a Randomization List?
A randomization list is a predefined schedule that assigns participants to different treatment groups using statistically valid, unbiased methods. This is fundamental to supporting internal validity, regulatory compliance, and data credibility.
Key Elements
- Subject ID: A unique identifier for each participant.
- Randomization Number: A sequence value that reflects the order of assignment.
- Treatment Group: Specifies whether the participant receives, for example, Drug A, Placebo, Device B, or a comparator.
- Stratification Factors(optional): Such as site, disease severity, or age group, to ensure balanced allocation.
- Randomization Timestamp(optional): Tracks the exact moment the assignment occurred.
How It’s Generated
Randomization lists are created using validated statistical software (e.g., SAS, R) following a predefined methodology, such as block, stratified, or minimization approaches. These lists are typically managed by an unblinded statistician or through an Interactive Web Response System (IWRS) or an IRT platform.
What Is a Kit List?
While the randomization list governs assignment, the kit list translates those assignments into dispensable drug or device kits used during the trial. It connects study subjects to the physical investigational products they are meant to receive, while preserving the blind where required.
Key Elements
- Randomization Number or Subject ID
- Kit Number: Corresponds to a specific package containing a drug, biologic, or device.
- Kit Expiry, Lot Number, and Status(optional): For traceability and inventory control.
- Blinded Indicators: The list does not reveal the treatment group directly, preserving trial blinding.
How Do These Lists Work Together?
The randomization list determines which group a subject is assigned to, while the kit list ensures they receive the correct investigational product at the time of administration. In blinded studies, only unblinded systems or personnel can access both lists in full.
This safeguards:
- Blinding of investigators and participants
- Proper kit dispensing and traceability
- Valid, analyzable data for regulatory submission
Why It Matters for All Trial Types
At BSC®, we support a wide range of trial designs across therapeutic areas and product classes. Whether you’re running a single-dose biologic trial, a diagnostic accuracy study, or a complex adaptive platform involving combination products, the quality of your randomization and kit tracking systems directly impacts regulatory defensibility and operational efficiency.
We perform randomization and kit list development with precision, tailored to your product, indication, and trial structure.
Planning a trial? Let’s make sure your foundation is bulletproof.
Contact the BSC® team to explore how we can optimize your randomization and dispensing strategy, without compromising scientific integrity or operational speed.
Congratulations to BSC®’s David Maislin, Alex Breno, and our friends at 3Spine on their recent publication!
The article lays out the protocol for the pivotal IDE trial behind 3Spine's MOTUS® lumbar Total Joint Replacement, the first device built to restore both disc and facet joint function without sacrificing motion.
WHAT CLIENTS SAY
“They listen the first time. I’ve never had to go back and respell out what I needed."
”They work to understand the problem and leverage the information that is already there.”
Former FDA Regulator
WHAT CLIENTS SAY
"Battle ground tested."
"There is nothing that David and team haven’t seen over the years – the good, bad, and ugly.”
Vice President, Clinical Operations
WHAT CLIENTS SAY
"Get stuff done when you have to do something no one else has done before."
"They aren’t afraid to tackle difficult scenarios in compressed timelines."
CEO, Medical Device Company
Regulatory-first biostatistics
Support built specifically for FDA-facing programs, from early feasibility through submission and post-market requirements.
Direct communication, faster turn around
Our biostatisticians write the SAP and run the analysis. One person owns both — no separate programmer, no project manager in between.
Versatile Solutions
Engage us for a focused analysis or a full submission, We size the work to the problem.
Proven FDA Experience
Hands-On Experience with FDA Pathways, statistical reviews, and regular interactions, reducing risk and rework.